{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:38:43Z","timestamp":1707525523016},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,20]]},"DOI":"10.7759\/cureus.50856","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:33:10Z","timestamp":1703118790000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Andexanet Alfa Induced Heparin Resistance in Emergent Aortic Surgery: Successful Anticoagulation Management Using Antithrombin Administration"],"prefix":"10.7759","author":[{"given":"Kazuyoshi","family":"Takagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomofumi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Saku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiki","family":"Tayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezad100","article-title":"Andexanet alfa in acute aortic syndrome: first UK experience","volume":"63","author":"Al-Attar N","year":"2023","unstructured":"Al-Attar N, Sedeek AF, McCall P, Travers J. Andexanet alfa in acute aortic syndrome: first UK experience. Eur J Cardiothorac Surg. 2023, 63:ezad100. 10.1093\/ejcts\/ezad100","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly SJ","year":"2016","unstructured":"Connolly SJ, Milling TJ Jr, Eikelboom JW, et al.. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016, 375:1131-41. 10.1056\/NEJMoa1607887","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2021.03.033","article-title":"STS\/SCA\/AmSECT\/SABM Update to the clinical practice guidelines on patient blood management","volume":"112","author":"Tibi P","year":"2021","unstructured":"Tibi P, McClure RS, Huang J, et al.. STS\/SCA\/AmSECT\/SABM Update to the clinical practice guidelines on patient blood management. Ann Thorac Surg. 2021, 112:981-1004. 10.1016\/j.athoracsur.2021.03.033","journal-title":"Ann Thorac Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2020.09.091","article-title":"Andexanet alfa use in cardiac surgical patients: A Xa inhibitor and heparin reversal agent","volume":"35","author":"Levy JH","year":"2021","unstructured":"Levy JH, Connors JM. Andexanet alfa use in cardiac surgical patients: A Xa inhibitor and heparin reversal agent. J Cardiothorac Vasc Anesth. 2021, 35:265-6. 10.1053\/j.jvca.2020.09.091","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1213\/XAA.0000000000001052","article-title":"Andexanet alfa for urgent reversal of apixaban before aortic surgery requiring cardiopulmonary bypass: A case report","volume":"13","author":"Flaherty D","year":"2019","unstructured":"Flaherty D, Connors JM, Singh S, Sylvester KW, Rimsans J, Cornella L. Andexanet alfa for urgent reversal of apixaban before aortic surgery requiring cardiopulmonary bypass: A case report. A A Pract. 2019, 13:271-3. 10.1213\/XAA.0000000000001052","journal-title":"A A Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2020.10.042","article-title":"Successful antithrombin administration in andexanet alfa-associated heparin resistance","volume":"35","author":"Apostel HJ","year":"2021","unstructured":"Apostel HJ, Winckers K, Bidar E, Schreiber JU. Successful antithrombin administration in andexanet alfa-associated heparin resistance. J Cardiothorac Vasc Anesth. 2021, 35:904-7. 10.1053\/j.jvca.2020.10.042","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5811\/cpcem.2019.9.43650","article-title":"Difficult intraoperative heparinization following andexanet alfa administration","volume":"3","author":"Watson CJ","year":"2019","unstructured":"Watson CJ, Zettervall SL, Hall MM, Ganetsky M. Difficult intraoperative heparinization following andexanet alfa administration. Clin Pract Cases Emerg Med. 2019, 3:390-4. 10.5811\/cpcem.2019.9.43650","journal-title":"Clin Pract Cases Emerg Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2306","article-title":"Intraoperative unfractionated heparin unresponsiveness during endovascular repair of a ruptured abdominal aortic aneurysm following administration of andexanet alfa for the reversal of rivaroxaban","volume":"39","author":"Eche IM","year":"2019","unstructured":"Eche IM, Elsamadisi P, Wex N, Wyers MC, Brat GA, Cunningham K, Bauer KA. Intraoperative unfractionated heparin unresponsiveness during endovascular repair of a ruptured abdominal aortic aneurysm following administration of andexanet alfa for the reversal of rivaroxaban. Pharmacotherapy. 2019, 39:861-5. 10.1002\/phar.2306","journal-title":"Pharmacotherapy"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s40981-023-00619-7","article-title":"Successful use of an antithrombin for heparin resistance with andexanet alfa","volume":"9","author":"Honda J","year":"2023","unstructured":"Honda J, Itakura Y, Tanaka S, Inoue S. Successful use of an antithrombin for heparin resistance with andexanet alfa. JA Clin Rep. 2023, 9:26. 10.1186\/s40981-023-00619-7","journal-title":"JA Clin Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44003","article-title":"Successful nafamostat mesilate administration for andexanet alfa-induced heparin resistance","volume":"15","author":"Kitaura A","year":"2023","unstructured":"Kitaura A, Iwamoto T, Hamasaki S, Tsukimoto S, Nakajima Y. Successful nafamostat mesilate administration for andexanet alfa-induced heparin resistance. Cureus. 2023, 15:e44003. 10.7759\/cureus.44003","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/215146-a-case-of-andexanet-alfa-induced-heparin-resistance-in-emergent-aortic-surgery-successful-anticoagulation-management-using-antithrombin-administration","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:13Z","timestamp":1707509413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/215146-a-case-of-andexanet-alfa-induced-heparin-resistance-in-emergent-aortic-surgery-successful-anticoagulation-management-using-antithrombin-administration"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.50856","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,20]]}}}